R

R&G PharmaStudies Co Ltd
SZSE:301333

Watchlist Manager
R&G PharmaStudies Co Ltd
SZSE:301333
Watchlist
Price: 49.6 CNY -4.39% Market Closed
Market Cap: 4.8B CNY
Have any thoughts about
R&G PharmaStudies Co Ltd?
Write Note

R&G PharmaStudies Co Ltd
Free Cash Flow

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

R&G PharmaStudies Co Ltd
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
R
R&G PharmaStudies Co Ltd
SZSE:301333
Free Cash Flow
ÂĄ172.7m
CAGR 3-Years
110%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Free Cash Flow
ÂĄ7.1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Free Cash Flow
ÂĄ370.8m
CAGR 3-Years
N/A
CAGR 5-Years
21%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Free Cash Flow
-ÂĄ313.4m
CAGR 3-Years
60%
CAGR 5-Years
16%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Free Cash Flow
ÂĄ677.7m
CAGR 3-Years
-10%
CAGR 5-Years
12%
CAGR 10-Years
N/A
W
WuXi XDC Cayman Inc
HKEX:2268
Free Cash Flow
-ÂĄ206.5m
CAGR 3-Years
-65%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

R&G PharmaStudies Co Ltd
Glance View

Market Cap
4.8B CNY
Industry
Life Sciences Tools & Services

R&G PharmaStudies Co., Ltd. engages in the provision of clinical trial outsourcing services. The company is headquartered in Beijing, Beijing and currently employs 1,926 full-time employees. The company went IPO on 2022-08-02. The firm's main businesses include clinical trial operation services (CO Services), clinical trial site management services (SMO Services), biological sample testing services (BA Services), data management and statistical analysis services (DM/ST Services), clinical trials Consulting Services, Clinical Pharmacology Services (CP Services) and others. The firm operates its businesses primarily in the domestic market.

Intrinsic Value
59.36 CNY
Undervaluation 16%
Intrinsic Value
Price
R

See Also

What is R&G PharmaStudies Co Ltd's Free Cash Flow?
Free Cash Flow
172.7m CNY

Based on the financial report for Dec 31, 2023, R&G PharmaStudies Co Ltd's Free Cash Flow amounts to 172.7m CNY.

What is R&G PharmaStudies Co Ltd's Free Cash Flow growth rate?
Free Cash Flow CAGR 3Y
110%

Over the last year, the Free Cash Flow growth was 58%. The average annual Free Cash Flow growth rates for R&G PharmaStudies Co Ltd have been 110% over the past three years .

Back to Top